


TAK-733

Cat. No.:	HY-13449
CAS No.:	1035555-63-5
Molecular Formula:	C ₁₇ H ₁₅ F ₂ IN ₄ O ₄
Molecular Weight:	504.23
Target:	MEK
Pathway:	MAPK/ERK Pathway
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 33 mg/mL (65.45 mM)
 * "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		1.9832 mL	9.9161 mL	19.8322 mL
	5 mM		0.3966 mL	1.9832 mL	3.9664 mL
	10 mM		0.1983 mL	0.9916 mL	1.9832 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (4.96 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	TAK-733 is a potent and selective MEK allosteric site inhibitor with an IC ₅₀ of 3.2 nM.
IC ₅₀ & Target	MEK 3.2 nM (IC ₅₀)
In Vitro	TAK-733 exhibits potent enzymatic and cell activity with an IC ₅₀ of 3.2 nM against constitutively active MEK enzyme and an EC ₅₀ of 1.9 nM against ERK phosphorylation in cells. TAK-733 does not inhibit any other kinases, receptors or ion channels that are tested with inhibitor concentrations up to 10 μM. TAK-733 is found to bind plasma protein moderately (ca. 97% for human and 96% for mouse), and exhibits high permeability and high microsomal stability across species. It does not inhibit P450s up to 30 μM ^[1] . TAK-733 demonstrates broad activity in most melanoma cell lines with relative resistance observed at IC ₅₀ > 0.1 μM in vitro. Thirty-four melanoma cell lines are exposed in vitro to increasing concentrations of TAK-733 for 72

hours. Of the 34 cell lines, 27 are BRAF^{V600E} mutant and 7 are wild-type. SRB proliferation assays are performed and the resulting IC₅₀ concentrations allowed stratification of cell lines into three categories: relatively resistant, intermediate, and highly sensitive. Relatively resistant and highly sensitive lines are assigned based on an IC₅₀ that differ by at least 10 fold^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The pharmacokinetics of TAK-733 is evaluated in nude mouse, rat, dog and monkey. Low clearance and high oral bioavailability are observed in all species. TAK-733 demonstrates broad antitumor activity in mouse xenograft models of human cancer including models of melanoma, colorectal, NSCLC, pancreatic and breast cancer^[1]. Daily oral administration of 1, 3, 10, and 30 mg/kg of TAK-733 for 14 days (Days 10 to 23) results in tumor growth delay in the A375 cell-implanted mice (5/group). TAK-733 (35, 70, 100, and 160 mg/kg) also significantly inhibits tumor growth on an intermittent dosing schedule of 3 days per week for 2 weeks (Days 10, 13, 15, 17, 20, and 22). Three partial regressions (PR), a 60% response rate, are observed in mice administered with 30 mg/kg of TAK-733 daily and in mice administered with 160 mg/kg of TAK-733 intermittently. Responses, CR (complete regression) and partial regressions (PR) are also observed in mice administered with 70, 100, and 160 mg/kg of TAK-733 intermittently. The tumor regression rate is more pronounced with the intermittent administration regimen; the greatest reduction in tumor volume is observed at 160 mg/kg (57.29%), versus a maximum reduction of 46.97% at 30 mg/kg once daily. By the last day of administration, tumor growth is significantly ($p < 0.05$ for %T/C, Student's t-test) inhibited in mice administered 3, 10, and 30 mg/kg once daily or 35, 70, 100, and 160 mg/kg intermittently^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay ^[2]

The cutaneous melanoma cell lines in logarithmic growth phase are transferred to 96 well flat bottom plates with lids. One hundred μ L cell suspensions containing 2000-3000 viable cells are plated into each well and incubated overnight prior to exposure with increasing concentrations of TAK-733 (10, 20, 30, 40, 50, 60, 70, 80, 90, and 100 nM) for 72 hours. Post drug administration, media is removed and cells are fixed with cold 10% trichloroacetic acid for 30 min. at 4°C. Cells are then washed with water and stained with 0.4% SRB for 30 min at room temperature, washed again with 1% acetic acid, followed by stain solubilization with 10 mM tris at room temperature. The absorbance at 565 nm is measured on a plate reader. Cell proliferation curves are derived from the raw absorbance (OD) data. Statistical analyses and graphical representation of data are using GraphPad Prism version 5.00^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration ^[2]

Mice^[2]

Five to six-week-old female athymic nude mice are used. A375 human melanoma xenograft tumors are generated by harvesting cells from mid-log phase cultures using Trypsin-EDTA. Approximately 5×10^6 cells suspended in Hanks' balanced salt solution (HBSS) are injected sc into the right flank of 6-8-week-old mice. Oral administration of TAK-733 (1 mg/kg or 10 mg/kg) is initiated when tumors in all mice in each experiment range in size from 100 to 200 mm³ for antitumor efficacy studies and from 300 to 500 mm³ for pharmacodynamic (PD) studies^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
- Exp Mol Med. 2018 Apr 20;50(4):37.
- J Invest Dermatol. 2021 Sep 14;S0022-202X(21)01672-9.
- ACS Comb Sci. 2019 Dec 9;21(12):805-816.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Dong Q, et al. Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer. *Bioorg Med Chem Lett*. 2011 Mar 1;21(5):1315-9.
- [2]. Micel LN, et al. Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants. *Mol Cancer Ther*. 2015 Feb;14(2):317-25.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA